¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"oxygen dependent killing"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • oxygen electrode method
    »ê¼ÒÀü±Ø¹ý
  • oxygen enhancement ratio
    »ê¼ÒÈ¿°úÁõ°­·ü, »ê¼ÒÁõ°­ºñ
  • oxygen fraction in inspired air
    ÈíÀÔ»ê¼Ò³óµµ
  • oxygen gain factor
    »ê¼ÒÀ̵æ°è¼ö
  • oxygen inhaler
    »ê¼ÒÈíÀÔ±â
  • oxygen manifold
    »ê¼Ò¹èºÐÀåÄ¡
  • oxygen mask
    »ê¼Ò¸¶½ºÅ©
  • oxygen monitor
    »ê¼Ò°¨½Ã±â
  • oxygen room
    »ê¼Ò½Ç
  • oxygen saturation
    »ê¼ÒÆ÷È­µµ
  • oxygen tank
    »ê¼ÒÅë
  • oxygen tent
    »ê¼ÒÅÙÆ®
  • oxygen therapy
    »ê¼Ò¿ä¹ý
  • oxygen tolerance
    »ê¼Ò³»¼º
  • oxygen toxicity
    »ê¼Òµ¶¼º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • total oxygen demand
    ¿Â»ê¼Ò¿ä±¸·®
  • inspired oxygen fraction
    Èí±â»ê¼ÒºÐÀ²
  • oxygen gain factor
    »ê¼ÒÀ̵æ°è¼ö
  • heavy oxygen
    Áß»ê¼Ò
  • hyperbaric oxygen
    °í¾Ð»ê¼Ò
  • oxygen hood
    »ê¼Ò¸Ó¸®µ¤°³, »ê¼ÒÈĵå
  • oxygen fixation hypothesis
    »ê¼Ò°íÁ¤°¡¼³
  • oxygen inhaler
    »ê¼ÒÈíÀÔ±â
  • liquid oxygen
    ¾×ü»ê¼Ò
  • oxygen manifold
    »ê¼Ò¹èºÐÀåÄ¡
  • oxygen monitor
    »ê¼Ò°¨½Ã±â
  • oxygen electrode method
    »ê¼ÒÀü±Ø¹ý
  • oxygen
    »ê¼Ò
  • oxygen requirement
    »ê¼Ò¿ä±¸·®
  • oxygen room
    »ê¼Ò½Ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • arterial blood oxygen tension
    µ¿¸ÆÇ÷»ê¼Ò Àå·Â.
  • arterial oxygen content
    µ¿¸ÆÇ÷»ê¼ÒÇÔÀ¯·®
  • arterial oxygen saturation
    µ¿¸ÆÇ÷ »ê¼ÒÆ÷È­µµ
  • arterial oxygen tension
    µ¿¸ÆÇ÷»ê¼ÒºÐ¾Ð, µ¿¸ÆÇ÷»ê¼ÒÀå·Â
  • arterial oxygen tension
    µ¿¸ÆÇ÷ »ê¼ÒºÐ¾Ð
  • arterial-venous oxygen content difference
    µ¿¸Æ-Á¤¸Æ»ê¼Ò¿ëÀûÂ÷ÀÌ
  • arterial-venous oxygen difference
    µ¿¸Æ-Á¤¸Æ »ê¼ÒÂ÷ÀÌ
  • arteriovenous oxygen content difference
    µ¿Á¤¸ÆÇ÷ »ê¼ÒÇÔ·®Â÷
  • arteriovenous oxygen difference
    µ¿Á¤¸ÆÇ÷ »ê¼Ò±³Â÷(¡­úìß«áÈÎòó¬)
  • arteriovenous oxygen tension difference
    µ¿Á¤¸ÆÇ÷ »ê¼ÒºÐ¾ÐÂ÷
  • biochemical oxygen demand =BOD
    »ý¹°È­ÇÐÀû »ê¼Ò¿ä±¸(·®)(ÊÙË×ËÛËíË´Ëâ).
  • biological oxygen demand =BOD
    »ý¹°ÇÐÀû »ê¼Ò¿ä±¸·®(ÊÙË×ËÛËíË´Ëâ).
  • biological oxygen demand =BOD
    »ý¹°ÇÐÀû »ê¼Ò¿ä±¸·®(¡­ß«áÈé©Ï´åÖ).
  • cardiac oxygen consumption
    ½ÉÀå»ê¼Ò¼Ò¸ð·®(ãýíôß«áÈá¼ÙÄÕá)
  • chemical oxygen demand =COD
    È­ÇÐÀû »ê¼Ò¿ä±¸·®(ÊÙË×ËÛËíË´Ëâ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ADC adult day care [facility]; affective disorders clinic; Aid to [Families with] Dependent Children; AI...
ADCC acute disorder of cerebral circulation; antibody-dependent cell-mediated cytotoxicity
ADE acute disseminated encephalitis; adverse drug event; antibody-dependent enhancement; apparent digest...
ADEE age-dependent epileptic encephalopathy
ADLC antibody-dependent lymphocyte-mediated cytotoxicity
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
DO Dissolved Oxygen
EOP Equivalent Oxygen Percentage
EPOC Excess post-exercise oxygen consumption
FIO2 Fractional inspired oxygen
FOR Free Oxygen Radicals
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
aid to families with dependent children Financial assistance provided by the government to indigent families with dependent children who meet certain requirements as defined by the social security act, title IV, in the u.s.
(12 Dec 1998)
androgen-dependent secretory protease <enzyme> Glycoprotein from dog prostate; hydrolyzes arginine and lysine-containing amide and ester protease substrates
Registry number: EC 3.4.99.-
Synonym: ads-protease
(26 Jun 1999)
antibody-dependent cell cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitised effector cells. The identity of the target cell varies, but it must possess surface IgG whose fc portion is intact. The effector cell is a "killer" cell possessing fc receptors. It may be a lymphocyte lacking conventional b- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.
(12 Dec 1998)
antibody-dependent enhancement Enhancement of viral infectivity caused by non-neutralizing antibodies. There are at least two mechanisms known to account for this: mediation by fc receptors (receptors, fc) or by complement receptors (receptors, complement). Either the virus is complexed with antiviral IgG and binds to fc receptors, or virus is coated with antiviral IgM and binds to complement receptors.
(12 Dec 1998)
aromatic NADH-dependent nitroreductase <enzyme> See also record for 1-nitroreductase; type I nitroreductase is not inhibited by oxygen
Registry number: EC 1.-
Synonym: nitrofuran reductase, nitrofurazone reductase, type I nitroreductases, NADH-dependent nitro reductase, nitrofurantoin reductase, p-dinitrobenzene reductase, benznidazole nitroreductase, nifurtimox nitroreductase, oxygen-insensitive NADPH nitroreductase, nitrobenzene nitroreductase
(26 Jun 1999)
aspartic acid 2-oxoglutarate-dependent dioxygenase <enzyme> Hydroxylates one aspartic acid residue in the first egf-like unit of factor ix
Registry number: EC 1.14.11.-
Synonym: aspartate 2-oxoglutarate dioxygenase, asp-2-og-dioxygenase, aspartyl beta-hydroxylase, aspartyl (asparaginyl) beta-hydroxylase
(26 Jun 1999)
ATP dependent 26S protease <enzyme> Degrades proteins conjugated to ubiquitin; composed of cf-1,cf-2, and cf-3; cf-2 (also known as 240-kD proteasome inhibitor) is identical to aminolevulinic acid dehydratase
Registry number: EC 3.4.99.-
Synonym: 26s protease, 26 s proteasome complex, 26s proteasome
(26 Jun 1999)
ATP-dependent DNA strand transferase <enzyme> From human cell nuclei; catalyses strand exchange between homologous DNA sequences; magnesium dependent, requires ATP hydrolysis
Registry number: EC 2.7.7.-
Synonym: ATP-dep-DNA-str trnsfase
(26 Jun 1999)
ATP-ubiquitin-dependent proteinase <enzyme> A component of the cytosolic ubiquitin-dependent proteolysis system
Registry number: EC 3.4.-
Synonym: ucden
(26 Jun 1999)
autophosphorylation-dependent multifunctional protein kinase <enzyme> A camp/ca(2+)-independent protein kinase; phosphorylates and activates phosphorylase b kinase; phosphorylates and inactivates glycogen synthase
Registry number: EC 2.7.1.-
Synonym: auto-kinase
(26 Jun 1999)
calcium-calmodulin-dependent phosphodiesterase <enzyme> Hydrolyzes both cgmp and camp; induced during mitogenesis
Registry number: EC 3.1.4.-
Synonym: ca-cam-phosphodiesterase, calmodulin-dependent cgmp phosphodiesterase
(26 Jun 1999)
calcium-calmodulin dependent protein kinase <enzyme> A calmodulin-dependent enzyme that catalyses the phosphorylation of proteins. This enzyme is also sometimes dependent on calcium. A wide range of proteins can act as acceptor, including vimentin, synapsin, glycogen synthase, myosin light chains, and the microtubule-associated proteins.
Registry number: EC 2.7.10.-
(12 Dec 1998)
calcium-dependent protein kinase <enzyme> Mw 51,000; requires ca; not stimulated by calmodulin, phospholipids or diacylglycerol; phosphorylates casein and histones forming primarily phosphoserine and phosphothreonine, respectively
Registry number: EC 2.7.1.-
Synonym: paramecium ca-dependent protein kinase
(26 Jun 1999)
calcium dependent regulator protein <protein> (CDRP) Early name for calmodulin.
(18 Nov 1997)
calcium dependent sulfhydryl protease <enzyme> Hydrolyzes actin binding protein; enzyme from platelets
Registry number: EC 3.4.22.-
Synonym: cdsp
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á